Overview

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining BMS-247550 with capecitabine in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy with a taxane and an anthracycline.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
R-Pharm
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine